Literature DB >> 20005342

Effects of delayed rapamycin treatment on renal fibrosis and inflammation in experimental ischemia reperfusion injury.

M Liu1, P Agreda, M Crow, L Racusen, H Rabb.   

Abstract

Ischemia reperfusion injury (IRI) has long-term sequelae on kidney allograft function. Early initiation of rapamycin can retard surgical wound healing and recovery from IRI. In contrast, rapamycin may paradoxically retard long-term fibrotic effects of kidney IRI. We, therefore, hypothesized that delayed initiation of rapamycin after kidney ischemia, started after the initial week of wound healing, would decrease the long-term inflammation and fibrosis caused by IRI. C57BL/6 male mice were subjected to either 45 or 60 minutes of unilateral kidney ischemia or a sham operation. Mice were given rapamycin (subcutaneous, 1.5 mg/kg/d) or vehicle starting at 1 week after IRI surgery for 3 weeks. Urine albumin excretion, kidney histology, and kidney cytokine proteins were examined at 4 weeks after surgery. The 3-week treatment course of rapamycin significantly reduced body weight gain in all 3 groups and reduced postischemic kidney weight in both the 45- and 60-minute ischemia groups, but unexpectedly increased urine albumin excretion in all rapamycin-treated sham or IRI mice compared with vehicle-treated mice. Rapamycin treatment showed minimal effects on postischemic kidney fibrosis with variable effects on various cytokine/chemokine protein expressions, namely, decreasing interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and regulated on activation normal T cell expressed and secreted (RANTES) while increasing IL-4, keratinocyte-derived chemokine (KC), macrophage inflammatory protein (MIP-1alpha), and IL-10 in the ischemic kidney. These data demonstrated that rapamycin reduced mouse body weight and ischemic kidney weight, while increasing urinary albumin excretion. Delayed initiation of rapamycin after IRI had a minimal effect on renal fibrosis and mixed effects on proinflammatory mediator production. These data do not support delayed initiation of rapamycin after IRI to attenuate IRI-induced progressive fibrosis and inflammation, and They raise further caution regarding rapamycin and albuminuria.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005342     DOI: 10.1016/j.transproceed.2009.08.083

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

Review 1.  Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies.

Authors:  António Nogueira; Maria João Pires; Paula Alexandra Oliveira
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

Review 2.  Role of T cells in ischemic acute kidney injury and repair.

Authors:  Kyungho Lee; Hye Ryoun Jang
Journal:  Korean J Intern Med       Date:  2022-04-28       Impact factor: 3.165

3.  The effects of sirolimus on target organs during mesenteric ischemia and reperfusion damage in an experimental rat model.

Authors:  Tamer Sagiroglu; Atakan Sezer; Semsi Altaner; Hasan Umit; Tulin Yalta; Mehmet Ali Yagci
Journal:  Curr Ther Res Clin Exp       Date:  2011-04

4.  Dendritic cell sphingosine 1-phosphate receptor-3 regulates Th1-Th2 polarity in kidney ischemia-reperfusion injury.

Authors:  Amandeep Bajwa; Liping Huang; Hong Ye; Krishna Dondeti; Steven Song; Diane L Rosin; Kevin R Lynch; Peter I Lobo; Li Li; Mark D Okusa
Journal:  J Immunol       Date:  2012-08-01       Impact factor: 5.422

5.  Activation of Sirt1 by resveratrol inhibits TNF-α induced inflammation in fibroblasts.

Authors:  Xiaoxia Zhu; Qiong Liu; Meimei Wang; Minrui Liang; Xue Yang; Xue Xu; Hejian Zou; Jianhua Qiu
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

6.  Rapamycin Alternatively Modifies Mitochondrial Dynamics in Dendritic Cells to Reduce Kidney Ischemic Reperfusion Injury.

Authors:  Maria Namwanje; Bijay Bisunke; Thomas V Rousselle; Gene G Lamanilao; Venkatadri S Sunder; Elizabeth C Patterson; Canan Kuscu; Cem Kuscu; Daniel Maluf; Manjari Kiran; Valeria Mas; James D Eason; Amandeep Bajwa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.